Santhera Targets New Indication with its Lead Compound
SNT-MC17 (idebenone) enters Phase IIa study in Duchenne muscular dystrophy
21-Oct-2005 -
Santhera Pharmaceuticals AG announced that it has started a Phase IIa clinical study with its lead product SNT-MC17 (idebenone) to evaluate its benefits in the treatment of Duchenne muscular dystrophy (DMD). DMD is the most common and devastating type of muscular dystrophy, causing weakness and ...
Belgium
clinical trials
Duchenne muscular dystrophy
+3